Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI2992

Abrogation of autoimmune diabetes in nonobese diabetic mice and protection against effector lymphocytes by transgenic paracrine TGF-beta1.

M Moritani, K Yoshimoto, S F Wong, C Tanaka, T Yamaoka, T Sano, Y Komagata, J Miyazaki, H Kikutani, and M Itakura

Otsuka Department of Clinical and Molecular Nutrition, School of Medicine, The University of Tokushima, Tokushima, Japan.

Find articles by Moritani, M. in: JCI | PubMed | Google Scholar

Otsuka Department of Clinical and Molecular Nutrition, School of Medicine, The University of Tokushima, Tokushima, Japan.

Find articles by Yoshimoto, K. in: JCI | PubMed | Google Scholar

Otsuka Department of Clinical and Molecular Nutrition, School of Medicine, The University of Tokushima, Tokushima, Japan.

Find articles by Wong, S. in: JCI | PubMed | Google Scholar

Otsuka Department of Clinical and Molecular Nutrition, School of Medicine, The University of Tokushima, Tokushima, Japan.

Find articles by Tanaka, C. in: JCI | PubMed | Google Scholar

Otsuka Department of Clinical and Molecular Nutrition, School of Medicine, The University of Tokushima, Tokushima, Japan.

Find articles by Yamaoka, T. in: JCI | PubMed | Google Scholar

Otsuka Department of Clinical and Molecular Nutrition, School of Medicine, The University of Tokushima, Tokushima, Japan.

Find articles by Sano, T. in: JCI | PubMed | Google Scholar

Otsuka Department of Clinical and Molecular Nutrition, School of Medicine, The University of Tokushima, Tokushima, Japan.

Find articles by Komagata, Y. in: JCI | PubMed | Google Scholar

Otsuka Department of Clinical and Molecular Nutrition, School of Medicine, The University of Tokushima, Tokushima, Japan.

Find articles by Miyazaki, J. in: JCI | PubMed | Google Scholar

Otsuka Department of Clinical and Molecular Nutrition, School of Medicine, The University of Tokushima, Tokushima, Japan.

Find articles by Kikutani, H. in: JCI | PubMed | Google Scholar

Otsuka Department of Clinical and Molecular Nutrition, School of Medicine, The University of Tokushima, Tokushima, Japan.

Find articles by Itakura, M. in: JCI | PubMed | Google Scholar

Published August 1, 1998 - More info

Published in Volume 102, Issue 3 on August 1, 1998
J Clin Invest. 1998;102(3):499–506. https://doi.org/10.1172/JCI2992.
© 1998 The American Society for Clinical Investigation
Published August 1, 1998 - Version history
View PDF
Abstract

Paracrine effect of transforming growth factor-beta1 (TGF-beta1) on autoimmune insulitis and diabetes was studied by transgenic production of the active form of porcine TGF-beta1 (pTGF-beta1) in pancreatic islet (islet) alpha cells in nonobese diabetic (NOD) mice under the control of rat glucagon promoter (RGP) (NOD-RGP-TGF-beta1). None of 27 NOD-RGP-TGF- beta1 mice developed diabetes by 45 wk of age, in contrast to 40 and 71% in male and female nontransgenic mice, respectively. None of the NOD-RGP-TGF-beta1 mice developed diabetes after cyclophosphamide (CY) administration. Adoptive transfer of splenocytes of NOD-RGP-TGF-beta1 mice to neonatal NOD mice did not transfer diabetes after CY administration. Adoptive transfer of three types of diabetogenic lymphocytes to NOD-RGP-TGF-beta1 and nontransgenic mice after CY administration led to the lower incidence of diabetes in NOD-RGP-TGF-beta1 mice versus that in nontransgenic mice: 29 vs. 77% for diabetogenic splenocytes, 25 vs. 75% for islet beta cell-specific Th1 clone cells, and 0 vs. 50% for islet beta cell-specific CD8(+) clone cells, respectively. Based on these, it is concluded that autoimmune diabetes in NOD mice is not a systemic disease and it can be completely prevented by the paracrine TGF-beta1 in the islet compartment through protection against CD4(+) and CD8(+) effector lymphocytes.

Version history
  • Version 1 (August 1, 1998): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts